TGTX - ティ―ジ―・セラピュ―ティクス (TG Therapeutics Inc.)

TGTXのニュース

   H.C. Wainwright Stick to Their Buy Rating for TG Therapeutics By Investing.com  2021/02/08 16:15:01 Investing.com
H.C. Wainwright Stick to Their Buy Rating for TG Therapeutics
   UKONIQ™ (umbralisib) Now Approved by the FDA; Onco360® Selected as Exclusive Specialty Pharmacy Partner  2021/02/08 16:00:00 Business Wire
LOUISVILLE, Ky.--(BUSINESS WIRE)--Onco360®, the nation’s largest independent Oncology Pharmacy, has been selected by TG Therapeutics, Inc. to be the exclusive specialty pharmacy partner for UKONIQTM (umbralisib), a new oral treatment for adult patients with relapsed refractory marginal zone lymphoma who have received at least one prior anti-CD20-based regimen and relapsed refractory follicular lymphoma who have received at least three prior lines of systemic therapy. These indications are appro
   HC Wainwright & Co. Maintains Buy on TG Therapeutics, Raises Price Target to $78  2021/01/19 06:22:00 Benzinga
This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of …
   B.Riley Financial Stick to Their Buy Rating for TG Therapeutics By Investing.com  2021/01/07 09:04:20 Investing.com
B.Riley Financial Stick to Their Buy Rating for TG Therapeutics
   Real Retirement Secrets: Your Most Important Investments! - BioSci Capital Partners  2020/12/31 02:32:16 Seeking Alpha
I feature a lot of big winners over the years inside IBI. Some of our big winners include TG Therapeutics (TGTX), CRISPR Therapeutics (CRSP), CryoPort (CYRX), Intra-Cellular Therapies (ITCI), Axsome Therapeutics (AXSM), Iovance Biotherapeutics (IOVA), Corium International (CORI), Kite Pharma(KITE), Juno Therapeutics (JUNO), Sparks Therapeutics (ONCE), Tesaro(TSRO), Mirati Therapeutics (MRTX), etc …
   HC Wainwright & Co. Maintains Buy on TG Therapeutics, Raises Price Target to $78  2021/01/19 06:22:00 Benzinga
This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of …
   B.Riley Financial Stick to Their Buy Rating for TG Therapeutics By Investing.com  2021/01/07 09:04:20 Investing.com
B.Riley Financial Stick to Their Buy Rating for TG Therapeutics
   Real Retirement Secrets: Your Most Important Investments! - BioSci Capital Partners  2020/12/31 02:32:16 Seeking Alpha
I feature a lot of big winners over the years inside IBI. Some of our big winners include TG Therapeutics (TGTX), CRISPR Therapeutics (CRSP), CryoPort (CYRX), Intra-Cellular Therapies (ITCI), Axsome Therapeutics (AXSM), Iovance Biotherapeutics (IOVA), Corium International (CORI), Kite Pharma(KITE), Juno Therapeutics (JUNO), Sparks Therapeutics (ONCE), Tesaro(TSRO), Mirati Therapeutics (MRTX), etc …
   IBI Blogs On Retirement Secrets: Three Cardinal Sins Deterring Your Luxurious Retirement - BioSci Capital Partners  2020/12/28 00:47:06 Seeking Alpha
Some of our big winners include TG Therapeutics (TGTX), CRISPR Therapeutics (CRSP), CryoPort (CYRX), Intra-Cellular Therapies (ITCI), Axsome Therapeutics (AXSM), Corium International (CORI), Kite Pharma(KITE), Juno Therapeutics (JUNO), Sparks Therapeutics (ONCE), Tesaro(TSRO), Mirati Therapeutics (MRTX), Iovance Biotherapeutics (IOVA), Mirati Therapeutics (MRTX), etc …
   JPMorgan says stocks are primed for sustained gains in a way they haven't been in years — and identifies 43 names to buy for above-average earnings growth in 2021  2020/12/17 13:15:00 Business Insider
Summary List Placement Despite the economic carnage caused by the worldwide COVID-19 outbreak, US stock indices have soared to all-time highs. That's mostly thanks to mega-cap tech firms, which have seen astonishing appreciation as work, school, and shopping have moved largely online. Now that vaccine rollouts have begun, the stay-at-home environment that boosted these growth stocks will start to change. Still, JPMorgan equity strategists — and their peers at other firms — expect the broader market to rise in 2021. The bank anticipates an up to 19% rally in the S&P 500 that's led mostly by cyclical and value stocks. But this doesn't mean stocks with rapid earnings growth will all suffer; for one, there are many whose valuations haven't skyrocketed like the tech firms at the top of the market. If the path ahead for the economic recovery becomes clearer, some growth stocks — in addition to recovery plays — will see the momentum needed to fuel their path upward. "The equity market is facing one of the best backdrops for sustained gains in years," Dubravko Lakos-Bujas, JPMorgan's chief US equity strategist, said in a recent note. "After a prolonged period of elevated risks (global trade war, COVID-19 pandemic, US election uncertainty, etc.), the outlook is significantly clearing up, especially with news of a highly effective COVID-19 vaccine. "Corporate earnings and labor market recovery continue to come in ahead of expectations," Dubravko continued.
   Real Retirement Secrets: Your Most Important Investments! - BioSci Capital Partners  2020/12/31 02:32:16 Seeking Alpha
I feature a lot of big winners over the years inside IBI. Some of our big winners include TG Therapeutics (TGTX), CRISPR Therapeutics (CRSP), CryoPort (CYRX), Intra-Cellular Therapies (ITCI), Axsome Therapeutics (AXSM), Iovance Biotherapeutics (IOVA), Corium International (CORI), Kite Pharma(KITE), Juno Therapeutics (JUNO), Sparks Therapeutics (ONCE), Tesaro(TSRO), Mirati Therapeutics (MRTX), etc …
   IBI Blogs On Retirement Secrets: Three Cardinal Sins Deterring Your Luxurious Retirement - BioSci Capital Partners  2020/12/28 00:47:06 Seeking Alpha
Some of our big winners include TG Therapeutics (TGTX), CRISPR Therapeutics (CRSP), CryoPort (CYRX), Intra-Cellular Therapies (ITCI), Axsome Therapeutics (AXSM), Corium International (CORI), Kite Pharma(KITE), Juno Therapeutics (JUNO), Sparks Therapeutics (ONCE), Tesaro(TSRO), Mirati Therapeutics (MRTX), Iovance Biotherapeutics (IOVA), Mirati Therapeutics (MRTX), etc …
   JPMorgan says stocks are primed for sustained gains in a way they haven't been in years — and identifies 43 names to buy for above-average earnings growth in 2021  2020/12/17 13:15:00 Business Insider
Summary List Placement Despite the economic carnage caused by the worldwide COVID-19 outbreak, US stock indices have soared to all-time highs. That's mostly thanks to mega-cap tech firms, which have seen astonishing appreciation as work, school, and shopping have moved largely online. Now that vaccine rollouts have begun, the stay-at-home environment that boosted these growth stocks will start to change. Still, JPMorgan equity strategists — and their peers at other firms — expect the broader market to rise in 2021. The bank anticipates an up to 19% rally in the S&P 500 that's led mostly by cyclical and value stocks. But this doesn't mean stocks with rapid earnings growth will all suffer; for one, there are many whose valuations haven't skyrocketed like the tech firms at the top of the market. If the path ahead for the economic recovery becomes clearer, some growth stocks — in addition to recovery plays — will see the momentum needed to fuel their path upward. "The equity market is facing one of the best backdrops for sustained gains in years," Dubravko Lakos-Bujas, JPMorgan's chief US equity strategist, said in a recent note. "After a prolonged period of elevated risks (global trade war, COVID-19 pandemic, US election uncertainty, etc.), the outlook is significantly clearing up, especially with news of a highly effective COVID-19 vaccine. "Corporate earnings and labor market recovery continue to come in ahead of expectations," Dubravko continued.
   BioXcel or TG Therapeutics: Which Biotech Stock Could Generate Triple-Digit Upside?  2020/12/13 14:12:16 Yahoo Finance
In 2020, biotechs have taken center stage. There are several biotech stocks that could generate stellar returns over the near future, according to Wall Street analysts. However, one should be aware that many of these stocks are risky as they are largely impacted by any news related to the development of their key drugs and regulatory approvals.Bearing this in mind, we will use TipRanks’ Stock Comparison tool to place BioXcel Therapeutics and TG Therapeutics alongside each other and select the biotech stock offering higher returns. We are talking about over 100% upside potential here.BioXcel Therapeutics (BTAI)BioXcel is a clinical-stage biopharma company that uses artificial intelligence to develop drugs across the neuroscience and immuno-oncology spaces. Currently, the company is not generating any revenue as it does not have any approved drugs on the market. That said, analysts are keeping an eye on the company’s two lead candidates, BXCL501 and BXCL701.BXCL501 is an orally dissolving thin film formulation of a popular sedative called Dexmedetomidine in late-stage development for the treatment of agitation resulting from neuropsychiatric disorders like schizophrenia and bipolar disorder.
   JPMorgan unveils its 50 'most compelling' stock picks to buy for 2021 — and details why each one will be a top performer  2020/12/13 13:03:07 Business Insider
Summary List Placement JPMorgan is decidedly bullish on stocks in 2021, to the point that it's telling investors they can haul in big returns with two diametrically opposed approaches. Chief US Equity Strategist Dubravko Lakos-Bujas says the benchmark S&P 500 should rally another 9% to 4,000 early next year. And by the end of the year, the benchmark index could climb to 4,500 for a gain of about 23% from today's levels — or 101% from its lowest closing price in March. For most of that recovery, high-growth stocks have outperformed — a pattern that's faded just in the last few weeks as investors felt a vaccine and a return to a post-virus normal was approaching. Lakos-Bujas and others say that investors should maintain exposure to growth, but combine it with bets on the right value stocks. "Investors should consider balancing out their portfolios to make sure they are not over-exposed to high Momentum/Growth stocks, which have outperformed during the pandemic," he said. The backdrop of globally synchronized expansion, legislative gridlock and positive vaccine news should be a strong catalyst for Value stocks." There are a lot of ways to combine those two approaches, and JPMorgan's analysts are offering investors a lot of options to put them into practice. "This report identifies what our analysts view as the most compelling investment ideas in their coverage group across a variety of strategies, including growth, value, near-term, and short strategies," said Head of North America Equity Research Nicholas Rosato Jr.

calendar